Fazio-Londe disease and Brown-Vialetto-Van Laere syndrome are rare related neurological disorders. Although and that encode riboflavin transporters are their only known causative genes, many patients without mutations in these genes have been reported. Clinical and genetic data of a patient with features suggestive of Fazio-Londe disease are presented. Neurological examination revealed significant involvement of cranial nerves and weakness in the lower extremities. Pontobulbar presentations were prominent. EDX study suggested motor neuronopathy. Hearing was normal. She was diagnosed with FL disease. Response to riboflavin supplementation was not favorable. The patient's pedigree suggested recessive inheritance. and were screened and mutations were not observed. Results of exome sequencing and segregation analysis suggested that a mutation in is a candidate cause of disease in the patient. The three dimensional structure of the TNRC18 protein was predicted and it was noted that its two conserved domains (BAH and Tudor) interact and that the valine residue affected by the mutation is positioned close to both domains. A mutation in is cautiously reported as the possible cause of FL disease in the patient. The finding warrants further inquiries on about which little is presently known.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10766555 | PMC |
http://dx.doi.org/10.1002/ccr3.8394 | DOI Listing |
Guillain-Barré syndrome (GBS) is characterized classically by progressive and symmetrical motor weakness and areflexia. We describe a case of GBS with initially preserved reflexes and power, leading to delayed diagnosis, who latterly required urgent ventilator support and plasmapharesis to highlight the importance of considering atypical presentations of this common condition.
View Article and Find Full Text PDFRadiographics
January 2025
From the Departments of Radiology (A.B.D., A.A., E.H.M., A.A.B., V.G.) and Neurology (A.S.M., K.H.M., S.L.C.), Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224; Department of Neurology, Mayo Clinic, Rochester, MN (N.K., E.S., E.P.F.); and Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy (E.S.).
IDCases
November 2024
Hospital Medicine Department, Integrated Hospital Care Institute, Cleveland Clinic Abu-Dhabi, PO BOX: 112412, Abu-Dhabi, United Arab Emirates.
Colistin, a polymyxin antibiotic, is increasingly used to manage infections caused by multidrug-resistant gram-negative bacteria. This case report documents the occurrence of colistin-induced neurotoxicity manifesting as bulbar palsy in a 38-year-old male with a complex medical history. The patient, presenting with septic shock secondary to a diabetic foot ulcer, was administered colistin and meropenem, leading to a progressive onset of neurological symptoms.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Ophthalmology and Visual Sciences (M.A.O.), Division of Genetics and Genomic Medicine (M.S.S.), and Division of Pediatric and Developmental Neurology (C.M.Z.), Washington University School of Medicine, St. Louis, MO; Graduate Medical Education Office (S.M.C.) and Department of Ophthalmology and Visual Neurosciences (S.M.C.), University of Minnesota Medical School, Minneapolis.
Riboflavin transporter deficiency (RTD), previously referred to as Brown-Vialetto-Van Laere syndrome, is caused by pathogenic variants in the , , or genes, resulting in RTD types 1, 2, and 3, respectively. Researchers estimate an occurrence of approximately 1 in 1,000,000. There is only one case of type 1 described in medical literature.
View Article and Find Full Text PDFAnn Neurosci
February 2024
Department of Geriatric Mental Health, King George's Medical University, Lucknow, Uttar Pradesh, India.
Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are less responsive to usual antiparkinsonian drugs. To assess the treatment outcome of the combination of low-dose amantadine and escitalopram in the study population. A retrospective study of PSP and MSA patients from June 2021 to December 2022 treated with the dose of amantadine 100 mg and escitalopram 5 mg per day with a follow-up of 2 months at a tertiary care centre in India.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!